Share chart Ironwood Pharmaceuticals, Inc.
Extended chart
Simple chart
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., медицинская компания, специализируется на разработке и коммерциализации продуктов для желудочно-кишечного тракта (ЖКТ). Компания продает линаклотид, агонист гуанилатциклазы типа C, для лечения взрослых, страдающих синдромом раздраженного кишечника с запором (IBS-C) или хроническим идиопатическим запором (CIC) под названием LINZESS в США и CONSTELLA в Канаде. more details| IPO date | 2010-02-03 |
|---|---|
| ISIN | US46333X1081 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.ironwoodpharma.com |
| Цена ао | 1.52 |
| Change price per day: | -6.39% (1.01) |
|---|---|
| Change price per week: | -29.44% (1.34) |
| Change price per month: | -38.6% (1.54) |
| Change price per 3 month: | -76.12% (3.96) |
| Change price per half year: | -77.96% (4.29) |
| Change price per year: | -88% (7.88) |
| Change price per 3 year: | -92.05% (11.89) |
| Change price per 5 year: | -90.5% (9.95) |
| Change price per year to date: | -73.22% (3.53) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Blackrock Inc. | 25980308 | 16.6 |
| Sarissa Capital Management, LP | 16390000 | 10.47 |
| Vanguard Group Inc | 16033545 | 10.24 |
| State Street Corporation | 11532088 | 7.37 |
| LSV Asset Management | 6782101 | 4.33 |
| Renaissance Technologies, LLC | 6595898 | 4.21 |
| Armistice Capital, LLC | 5700000 | 3.64 |
| Credit Suisse Ag/ | 5612113 | 3.59 |
| Victory Capital Management Inc. | 4224583 | 2.7 |
| Brown Capital Management, LLC | 3709431 | 2.37 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Syntax Stratified SmallCap ETF | 0.13994 | 13.51 | 1.639 |
| Future Tech ETF | 0.06629 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.06629 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Value ETF | 0.02674 | 197.28 | 2.50476 |
| iShares Morningstar Small-Cap ETF | 0.01291 | 391.25 | 1.60498 |
| 0.06 | 329.38 | 1.48 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Thomas A. McCourt | CEO & Director | 1.42M | 1957 (68 years) |
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior VP and Head of Research & Drug Development | 837.74k | 1959 (66 years) |
| Mr. Ronald Silver | Corporate Controller & Principal Accounting Officer | N/A | 1983 (42 years) |
| Mr. John Minardo | Senior VP, Chief Legal Officer & Secretary | 675.88k | 1976 (49 years) |
| Mr. Sravan Kumar Emany | Senior VP, CFO & COO | 712.36k | 1978 (47 years) |
| Ms. Beth Calitri | VP of Corporate Communications & Media Relations | N/A | |
| Greg Martini | Vice President of Strategic Finance & Investor Relations | N/A | |
| Mr. Mike Nanfito | Vice President of Sales & Sales Excellence | N/A | |
| Mr. Andrew Davis | Senior VP & Chief Business Officer | 1987 (38 years) | |
| Dr. Susanna Y. Huh M.D., M.P.H. | VP & Head of Clinical Development |
Address: United States, Boston, 100 Summer Street - open in Google maps, open in Yandex maps
Website: https://www.ironwoodpharma.com
Website: https://www.ironwoodpharma.com
